Products Affected - Description
Bactroban topical cream, GlaxoSmithKline
2%, 15 gm tube, 1 count (NDC 00029-1527-22)
2%, 30 gram tube, 1 count (NDC 00029-1527-25)
Mupirocin calcium topical cream, Prasco
2%, 15 gram tube, 1 count (NDC 66993-0942-15) - discontinued
2%, 30 gram tube, 1 count (NDC 66993-0942-31) - discontinued
Reason for the Shortage
- GlaxoSmithKline could not provide a reason for the shortage.
- Prasco discontinued mupirocin calcium 2% cream in February 2016.
Mupirocin calcium topical cream, Glenmark
2%, 15 gram tube, 1 count (NDC 68462-0564-17)
2%, 30 gram tube, 1 count (NDC 68462-0564-35)
Estimated Resupply Dates
GlaxoSmithKline has Bactroban 2% cream in 15 gram and 30 gram sizes on back order and the company estimates a release date of 1st quarter 2017.
July 22, April 14, February 29, January 20, 2016; November 25 and 11, October 8, September 4, 2015, University of Utah, Drug Information Service. Copyright 2016, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins